Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: A population-based analysis

Clinical Colorectal Cancer

Volumn 5, Issue 4, 2005, Pages 279-282

  Ho, Cheryl ^a   Ng, Kathy ^a   O'Reilly, Susan ^a   Gill, Sharlene ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Palliative chemotherapy; Temporal trends; Tolerability; Toxicity

Indexed keywords

CAPECITABINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG DERIVATIVE; PLATINUM COMPLEX;

AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GERIATRIC CARE; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; POPULATION RESEARCH; REGISTER; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC THERAPY; TIME SERIES ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; AGE; CANCER STAGING; COLORECTAL TUMOR; MORTALITY; PATHOLOGY; SURVIVAL;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; COHORT STUDIES; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33644839465     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2005.n.040     Document Type: Article

References (23)

1. Canadian Cancer Society. Colorectal Cancer Stats. Available at: http://www.cancer.ca/ccs/internet/standard/0,3182,3172_14447_langId- en,00.html. Accessed March 1, 2005.
2. American Cancer Society. Statistics for 2004. Available at: http://www.cancer.org/docroot/STT/stt_0_2004.asp?sitearea= STT&level=1. Accessed March 1, 2005
3. National Cancer Institute. Statistics, Epidemiology, and End Results Statsistics Review, 1975-2001. Available at: http://seer.cancer.gov/csr/ 1975_2001/results_merged/topic_age_dist.pdf. Accessed March 1, 2005.
4. Thirion P, Michiels S, Pignon JP, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004; 22:3766-3775.
5. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-914.
6. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947.
7. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-1047.
8. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21:2059-2069.
9. Gill S, Goldberg RM. First-line treatment strategies to improve survival in patients with advanced colorectal cancer. Drugs 2004;64:27-44.
10. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19:4097-4106.
11. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19:2282-2292.
12. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341:2061-2067.
13. Trimble EL, Carter CL, Cain D, et al. Representation of older patients in cancer treatment trials. Cancer 1994; 74(7 suppl):2208-2214.
14. Sundararajan V, Grann VR, Jacobson JS, et al. Variations in the use of adjuvant chemotherapy for node-positive colon cancer in the elderly: a population-based study. Cancer J 2001; 7:213-218.
15. Schrag D, Cramer LD, Bach PB, et al. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 2001; 93:850-857.
16. Yancik R, Wesley MN, Ries LA, et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer 1998; 82:2123-2134.
17. Folprecht G, Cunningham D, Ross P, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 2004; 15:1330-1338.
18. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345:1091-1097.
19. Popescu RA, Norman A, Ross PJ, et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999; 17:2412-2418.
20. D'Andre S, Sargent DJ, Cha SS, et al. 5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: a north central cancer treatment group study. Clin Colorectal Cancer 2005; 4:325-331.
21. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J Clin Oncol 1998; 16:3537-3541.
22. Jonker DJ, Vincent M, Kerr I, et al. Dose reduced first-line capecitabine monotherapy in older and less fit patients with advanced colorectal cancer. In: Proceedings of 2004 Gastrointestinal Cancers Symposium; January 22-24, 2004; San Francisco, CA. Abstract #212.
23. Feliu J, Escudero F, Losa M, et al. A phase II study of capecitabine in elderly patients as 1st line treatment for patients with advanced or metastatic colorectal cancer. Proc Am Soc Clin Oncol 2004; 23:262 (Abstract #3567).